The mineralized matrix of bone makes it difficult to examine specific populations of cells which are integral to the tissue using traditional molecular methods. For this study we examined single cell cortical osteoblasts derived from the femurs of C57BL/6J mice.
Abstract-
The mineralized matrix of bone makes it difficult to examine specific populations of cells which are integral to the tissue using traditional molecular methods. For this study we examined single cell cortical osteoblasts derived from the femurs of C57BL/6J mice.
After isolating single cells from bone, we were able to individually analyze their gene expression profiles using the quantitative polymerase chain reaction (qPCR). The mice used for the study were divided into 4 treatment groups, including ovariectomized mice These results will help demonstrate how estrogen deficiency and the prevention of bone loss with anti-resoprtives specifically alter the gene expression profiles of primary cortical osteoblasts at the single cell level.
Background:
Bone remodeling is the process in which bone is continuously replaced by new tissue, often in response to fractures or micro damage that occur normally in order to repair damaged bone. It is involved in the maintenance of systemic calcium homeostasis, replacing damaged bone, and controlling the growth and development of bone(1). Remodeling occurs due to mechanical stress, hormonal changes and in order to maintain the bone mineral homeostasis. Bone remodeling displays three distinct stages of skeletal growth in humans (2) . During childhood bone remodeling leads to skeletal growth that reaches homeostasis at adulthood and with increased age leads to a net loss of bone. Bone itself consists of an extracellular mineralized matrix, collagen and cells. Bone remodeling is modulated by two important cell populations, osteoclasts and osteoblasts (3) . Osteoclasts are large, multinucleate cells that have abundant Golgi complexes and lysosomal enzymes. They are responsible for bone resorption on the surface of cells through the creation of resorption pits (also known as basic multicellular units, or BMUs). Osteoclasts resorb bone through the processes of acidification and proteolysis of the mineralized matrix. The other cell type, osteoblasts, are responsible for the formation of new bone matrix in the resorption pits created by osteoclasts.
Osteoblasts cell are derived from multipotent mesenchymal stem cells which have the potential to differentiate into several cell types including adipocytes, fibroblasts and osteoblasts. Collagen I, the main structural protein within bone, is one of the first proteins synthesized by osteoblasts during bone formation, followed by several nonstructural proteins. Osteoblasts complete bone formation by the mineralization of the matrix of the bone. About 15% of mature osteoblasts are eventually embedded into the bone matrix, some of which progress in differentiation to become osteocytes.
Osteocytes are cells within the bone that are responsible for mechano-transduction, and modulate the activity of osteoblasts and osteoclasts. The two main types of bone found within the skeleton are known as cortical and trabecular bone. Cortical bone supports the body, protects the organs and is very dense. Cortical bone forms the outer shell of bone and makes up the majority of weight in the human skeleton. Trabecular bone, also known as spongy bone, has a high surface area and contains red bone marrow. Its large surface area facilitates metabolic activity and production of blood cells. Unlike humans, female mice do not undergo menopause, although they do become infertile at around 11 to 16 months of age. The OVX mouse serves as a model for accelerated bone loss of trabecular and cortical bone because it mimics the effects of menopause from estrogen deficiency (11) . The OVX mouse loses bone via estrogen deprivation due to surgical removal of the ovaries (12, 13) . This makes the OVX mouse an effective model for mimicking osteoporosis in humans due to menopause. The rate of normal age-related bone loss has been shown to be well defined and consistent within a number of inbred mouse strains which makes it possible to distinguish between bone loss due to normal aging and bone loss due to estrogen deficiency (14) . C57BL/6J mice normally start losing trabecular bone as early as 6 weeks of age, and this continues up until 24 months of age, while cortical bone mass peaks at around 6 months of age before it starts to decline(2). The ovariectomy surgery is known to have a strong effect on both the trabecular and cortical bone health of the C57Bl/6J mouse (12) .
MicroCT, or x-ray imaging in 3D at a high resolution, can be used to evaluate the micro-architecture of both cortical and trabecular bone. CT scans can be performed in vivo at a low resolution or ex vivo using collected tissues at a high resolution resulting in a more detailed and precise quantification of bone metrics. CT scans are one of the more effective ways of diagnosing osteoporosis because it can be used to determine various bone health metrics for both cortical and trabecular bone non-invasively. These metrics include, but are not limited to, bone volume versus tissue volume, trabecular separation and cortical thickness.
Gene expression analysis is an important tool in biology that is typically (21). This is accomplished by labeling proteins with a fluorophoreconjugated antibody that is only found within the desired cell population (14, 22) . Single cell analysis can use cells isolated directly from the source, which avoids potential problems of using cells grown in vitro that may include potential differences in cell behavior, specific location and physiological state of the cells(23).
Summary:
The human skeleton is a complex organ incorporating functions that include blood cell production, supporting the body, calcium storage and endocrine regulation.
Osteoporosis is a serious age-related disease that affects a large population, with an estimated 2 million fractures a year, and whose health effects have an annual impact of around $17 billion a year in the United States (24, 25) . Osteoporosis causes low bone mineral density and weakened bone architecture, and leads to an increased risk of bone fractures that at a later ages leads to high mortality rates. In recent years, there have been several breakthroughs in treating age-related bone disorders such as osteoporosis. This progress has been in part accomplished with the creation of successful animal models that mimic age-related bone loss. A well-accepted animal model of bone loss is the ovariectomized (OVX) mouse. Currently, many studies examining bone and the mechanisms of bone loss use cell culture models, or employ total bone cell homogenates (26, 27) . This method of study is often used because of the difficulty of studying bone cells due to the fact that they are usually encased within an ossified matrix. Using cell cultures is not ideal because it is not well understood how osteoblasts transcriptionally vary from one type of bone to another (28) . It can also be argued that this approach is suboptimal with regards to appreciating the potential importance of physiological or genetic changes in key cell types within the bone. The
Melov laboratory has developed a methodology for isolating osteoblasts (the cell type (CD31-/CD45-/AP+), and then collected using FACS. The isolated osteoblasts were then assayed using qPCR for a set of 96 bone specific genes found within osteoblast populations. This set of specific genes was refined through several control qPCR runs of osteoblasts obtained from C57/BL6J mice. These optimizing qPCR runs were used in order to eliminate any genes that showed no gene expression in the control osteoblasts.
We supplemented new genes using current literature in the field of bone and osteoblast research (29) (30) (31) . These genes included, but were not limited to, sclerostin, an indirect inhibitor of bone formation, AEbp1, a gene that plays a role in adipogenesis and has been found in osteoblasts, and Sox2.
This study will provide the first single cell osteoblast transcriptional profile derived in vivo from the OVX mouse model. This paradigm is used to assess the in vivo skeletal phenotypes and subsequently relate them to the gene expression changes in freshly isolated cells from the bones of treated versus non treated animals. This study will also
show the effects of bisphosphonate (Alendronate) treatment within the transcription profiles of single cells during bone loss due to estrogen loss.
Materials and Methods

Animal Models and Treatment
The mice used in this study were obtained as a single cohort from Charles River Laboratories. The mice had OVX or SHAM surgeries performed on them at 2 months of age by the vendor, and after sufficient recovery time, the mice were shipped to our facility. On arrival the mice were tattooed with a number (1-40) on their tail to aid in identification. The mice were monitored for their health status throughout the study, and weighed every week for a 16-week period. The weights of the individual mice were used to determine the amount of Alendronate administered, and to record the expected weight gain due to estrogen deficiency. Mice that were on bisphosphonate treatment were given a weekly I.P. injection of 100 µg/kg of Sodium Alendronate (Sigma Aldrich).
After 16 weeks of treatment, the mice were euthanized and tissues were collected for analysis. During the euthanasia, all of the mice were visually inspected for the success of the OVX or sham surgery. This was done by looking for the characteristic atrophy normally found within the uterine horns of OVX mice. All animal procedures conformed to Buck Institute IACUC guidelines and AAALAC standard operating procedures
MicroCT Analysis
All of the mice were scanned by µCT in vivo at a 35 µm resolution at arrival and a week before they were euthanized. When euthanized, at the end of their treatment, tissues were harvested from the entire cohort of mice in order to preform ex vivo scans.
The lumbar of the spine and half of the right femurs from each treatment group were collected and preserved in 10% neutral buffered formalin. Both of these tissues were scanned at a 9µm resolution, which allowed for more detailed measurements than that 
Single Cell Collection and Analysis
After the mice were euthanized, the isolated femurs were cleaned, and epiphyses from both ends were removed, and the resultant diaphysis was subsequently flushed with PBS in order to remove the majority of marrow and hematopoietic cells from the femur. Once the femurs had been cleaned they were then preserved in a modified media and stored at -80° C as described in Flynn et al (16) . 
Single Cell Gene Expression
The isolated individual osteoblasts cells were assayed using a single cell qPCR procedure. The procedure uses direct reverse transcription and specific target amplification prior to microfluidic qPCR. The individual cells were isolated using a micromanipulator and then placed in PCR tubes with a small volume of 1-2 µl that were then immediately frozen on dry ice and then stored at -80° C. When the qPCR was ready to be performed the cells were thawed on ice. Then the cells were pre-amplified using specific target amplification of relevant genes containing all 96 assay primers sets for 18 cycles using the Cell-Direct RT-qPCR kit (Invitrogen). The single cell pre-amplified product was then diluted 1:5 in a DNA suspension buffer and then assayed using Fluidigm's 96.96 nanofluidic qPCR on a Biomark HD system. Biotium's EvaGreen DNA binding dye was used to detect amplified product according to Fluidigm's advanced development protocol #30 (23) . The exported qPCR data files were then normalized using Singular R analysis package (v1, Fluidigm) in order to obtain Log2Expression values for each reaction.
Statistical analysis
All of the statistical comparisons for this study were tested using a nonparametric randomization test using the statistical software R (16) . Treatment groups were compared and the null was rejected if p<0.05. These statistical tests were performed in order to avoid the assumption of a normal distribution within our samples, especially for the single cell gene expression analysis. Pairwise comparisons were made using permutation test and multiple testing correction was applied to identify differential gene expression (Benjamini-Hochberg. 5% FDR). The CT statistical analysis was performed by comparing the statistical differences between the specific treatment groups including: SHAM versus OVX, SHAM versus OVX+ALD, SHAM versus SHAM+ALD and OVX versus OVX+ALD. ANOVA P-value testing was used to determine the statistical differences in gene expression for each treatment group.
Results
In order to derive a source for our osteoblast lineage cells we obtained a cohort of 40, 2-month old C57BL/6J mice. Half of the mice had OVX surgery performed while the other half had a SHAM surgery. Once at our facility the mice were divided into four groups of 10, with one group from each surgical treatment receiving Alendronate (100 µg/kg) treatment once every week via I.P. injection. This resulted in 4 treatment groups:
OVX, OVX+ALD, SHAM and SHAM+ALD. After a 16 week period, the mice were euthanized and tissues were collected for osteoblast cell collection for qPCR and CT scans (Figure 1 ).
Estrogen Depleted Bone Loss is attenuated or reversed by Alendronate
The weights of the mice were closely monitored in order to determine the success or failure of the OVX surgery (Figure 2) , as occasionally the surgical procedure is not successful. The OVX estrogen deficient mice showed the expected weight gain at approximately 59 to 66 days post-surgery when compared to the SHAM controls. This elevated weight gain was maintained for the full 16 weeks in the OVX group. However by the end of the 16 week treatment, the OVX+ALD weights were not significantly different from the SHAM treatments. There was no statistically significant difference in weights between the SHAM and SHAM+ALD treatment groups throughout the study.
After the mice were euthanized for tissue collection their uterine horns were visually inspected for atrophy ( Figure 2) . All of the OVX treatment mice showed clear atrophy in their uterine horns, as expected, while the SHAM mice had uterine horns that had
proper blood flow and normal appearance, confirming that the OVX procedure was successful in the OVX mice used in this study.
In order to show that estrogen deficiency results in bone loss in mice and that treatment with Alendronate can modulate/attenuate these effects, and even lead to greater bone mass, spines and femurs were collected for 3D visualization via CT scans. 
Single cell gene expression of isolated osteoblast cells
Once it was established that both the ovariectomy procedure and the pharmacological intervention were affecting bone loss as expected we moved on to isolating the single cell osteoblasts from the femurs of the mice using a previously Once the efficacy of the surgery was determined, via tracking of the expected weight gain and visual inspection of atrophy within the uterine horns of the mice, we wanted to confirm the expected bone phenotypes. High-resolution microCT scans of both the spine and femur were used to confirm that estrogen deficiency caused bone loss and that Alendronate treatment could lead to improved bone health. The CT data showed that estrogen deficiency had a significantly negative impact on both trabecular and cortical bone health metrics and that Alendronate treatment was able to slow or reverse much of the bone loss seen in the OVX mice and even improved bone health metrics in the SHAM control mice. Alendronate treatment was only able to lead to significantly increased cortical bone health in the SHAM mice but a clear trend towards increased bone health was seen in the OVX mice. These microCT results allowed us to confirm that the each treatment group altered bone health metrics as expected.
With the osteoblast lineage cells successfully isolated, qPCR was performed for 96 genes in order to generate gene expression profiles for all of the collected cells. The overall expression of mRNA within these cells was low but measurable when compared to other cell types (23) . The principal component analysis of the expression data showed that neither the estrogen depletion nor the Alendronate treated cells seemed to segregate based solely on individual treatment group. However when the expression levels for each gene were analyzed many differentially expressed genes were identified.
The most common expression profile found within our selected genes had higher levels of expression in the OA, S and SA treatment cells. These genes had significantly lower expression levels in the OVX treated cells and saw restored expression levels in OVX mice that were treated with Alendronate. These results suggest that these genes are responsible for modulating bone loss in this model. This conclusion seems likely as many of the genes found in this expression profile are known to be responsible for bone formation and osteoblast development, such as Axl4, BMP7, IGF1 and Osterix. These expression profiles may account for the poor bone health metrics found in the OVX mice and the improved bone health observed in the OVX+ALD treatment mice. We examined the profiles of genes within this expression profile for any interesting expression changes that could validate the biological changes seen in the bones of the mice used in this study. One gene that stood out was IGF1 which is known to be a key gene in the beneficial effects on bone health, even with its negative effects on IGF1, as it was highly expressed in OA, S and SA treatment groups, the treatment groups that had best bone health metrics.
The other major expression profile we discovered in our qPCR data had genes with higher expression in all treatment groups except for the SHAM treatment cells.
Genes within this expression profile had several different functions but there were many genes, such as ND3, CYTB and ND4L, which had mitochondrial related functions. The increased expression of mitochondrial genes could indicate higher levels of mitochondria, and an increase in energy production in the osteoblast cells which would be expected to improve the rate of bone formation. This would help to explain why the SHAM+ALD mice had improved bone health metrics when compared to the SHAM mice. Interestingly, these genes were also more highly expressed in the OVX treatment cells but it does not seem like their increased expression is sufficient for bone development.
There were several genes that showed higher expression levels in only the SHAM treatment groups. These genes appear to be unaffected by Alendronate treatment in our osteoblast cells. In order to analyze bone loss from the area in which the osteoblast cells were derived femurs (n= 5 per group, p<0.05) were collected for each treatment group. The femurs were scanned by µCT, ex vivo, at a high resolution (9um). The cortical bone, the midshaft of the bone, and the trabecular bone, a section of the growth plate, were analyzed using standard bone metrics. The mean crossectional area and thickness of the femur midshaft were significantly reduced in the OVX treatment versus the SHAM control while the overall bone volume showed no significant difference. The trabecular BV/TV, and Tr. Number were both significantly higher, along with a significant decrease in Tr. Separation, in both of the alendronate treatment groups. In the trabecular bone there is significant difference in Tr. separation between OVX and SHAM treatment mice. There is also a small but still significant decrease in BV/TV and Tr. number in the OVX versus SHAM mice. This indicates that there is still a potential change in the bone architecture of the femur due to estrogen deficiency. AEBP1  Axl4  BGLAP  BGN  BMAL1  BMP6  BMP7  BTG2   CCNA2  CCNB1  CCR6  CCRN4L  CD105  CD31  CD44  CD45   CD5  CD79A  CD79B  CDK2  CDKN1B  CHRNA1  CKIP1  COL1A1   COL1A2  COX1  COX2  CRYAB  CTNNB1  CXCL12  CXCR4  CYC1   CYP51  CYTB  EFNB2  EPHB4  FGF21  FOXO1  FOXO3  HLA_DR   ID4  IGF1  IGFBP2  IGFR1 Figure 5 . This table shows all 96 bone and osteoblast related genes that were used for the qPCR assays of the single cell isolated osteoblasts obtained in this study. The genes selected were mainly bone specific and bone related genes along with some cell cycle and mitochondrial related genes. The genes were clustered in order to identify any expression profiles among the 4 treatment groups of osteoblast cells. Along the side of each row of the heat map cells were labeled with their treatment group and the animal ID from which they were originally derived. This was done to determine if any of the expression patterns were due treatment group or the individual mouse they were derived from. All expression data from the osteoblast qPCR runs was used to find the Log2 Expression levels for all 96 genes we examined in this study. The Log2 Expression levels were than used to create violin plots for the expression values of all 96 genes for each treatment group (S = SHAM, SA = SHAM + ALD, O = OVX, and OA = OVX + ALD). Genes were organized due to differential expression among the four treatment groups, with those having the greatest differential expression located at the top left of the figure and genes with the lowest differential expression found at the bottom right section of the figure.
Genes used for qPCR Assays
